ES2130257T3 - Nuevos compuestos y conjugados. - Google Patents

Nuevos compuestos y conjugados.

Info

Publication number
ES2130257T3
ES2130257T3 ES93909297T ES93909297T ES2130257T3 ES 2130257 T3 ES2130257 T3 ES 2130257T3 ES 93909297 T ES93909297 T ES 93909297T ES 93909297 T ES93909297 T ES 93909297T ES 2130257 T3 ES2130257 T3 ES 2130257T3
Authority
ES
Spain
Prior art keywords
compound
group
analyzes
conjugates
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93909297T
Other languages
English (en)
Inventor
Paul S Palumbo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Behring Diagnostics Inc
Original Assignee
Behring Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behring Diagnostics Inc filed Critical Behring Diagnostics Inc
Application granted granted Critical
Publication of ES2130257T3 publication Critical patent/ES2130257T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

UN COMPUESTO REPRESENTADO POR FORMULA (I), EN DONDE X ES UN GRUPO SEPARADOR. EL COMPUESTO SE USA PARA CONJUGAR UN COMPUESTO QUE TIENE UN GRUPO ALCOHOL SOBRE UN GRUPO AMINA A UN COMPUESTO QUE TIENE UN GRUPO TIOL. EL COMPUESTO PUEDE SER USADO PARA CONJUGAR UN GRUPO BIOLOGICAMENTE ACTIVO TAL COMO UN ANTIGENO O UNA PROTEINA TAL COMO UNA ENZIMA PARA PROPORCIONAR UNA ENZIMA ANTIGENO ETIQUETADA PARA USO EN METODOS DE INMUNOENSAYO DE AMPLIFICACION DE ENZIMA PARA ANALITOS O METABOLITOS EN MUESTRAS FLUIDAS. EL COMPUESTO TAMBIEN SE PUEDE USAR PARA INMOBILIZAR UN MATERIAL TAL COMO UNA PROTEINA A UN SOPORTE SOLIDO.
ES93909297T 1992-04-23 1993-04-08 Nuevos compuestos y conjugados. Expired - Lifetime ES2130257T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/872,539 US5294536A (en) 1992-04-23 1992-04-23 Conjugates

Publications (1)

Publication Number Publication Date
ES2130257T3 true ES2130257T3 (es) 1999-07-01

Family

ID=25359788

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93909297T Expired - Lifetime ES2130257T3 (es) 1992-04-23 1993-04-08 Nuevos compuestos y conjugados.

Country Status (9)

Country Link
US (1) US5294536A (es)
EP (1) EP0606411B1 (es)
JP (1) JPH06508639A (es)
AT (1) ATE177113T1 (es)
AU (1) AU662627B2 (es)
CA (1) CA2101734A1 (es)
DE (1) DE69323713T2 (es)
ES (1) ES2130257T3 (es)
WO (1) WO1993022677A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU670674B2 (en) * 1993-01-06 1996-07-25 Beckman Instruments, Inc. Method for making a preconjugate
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
US5869465A (en) * 1994-04-08 1999-02-09 Receptagen Corporation Methods of receptor modulation and uses therefor
US5739287A (en) * 1994-04-08 1998-04-14 University Of Washington Biotinylated cobalamins
CA2187346C (en) * 1994-04-08 2010-06-29 A. Charles Morgan, Jr. Receptor modulating agents and methods relating thereto
SE9600229D0 (sv) * 1996-01-23 1996-01-23 Pharmacia Ab Novel potentiating agents
EP1011729B1 (en) * 1996-05-20 2008-01-09 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligonucleotides which specifically bind retroviral nucleocapsid proteins
DE19636889A1 (de) * 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
US5977299A (en) * 1997-04-07 1999-11-02 Dade Behring Marburg Gmbh Activated peptides and conjugates
AUPP405098A0 (en) * 1998-06-12 1998-07-02 Access Pharmaceuticals Australia Pty Limited Novel methods of preparation of vitamin b12 derivatives suitable for conjugation to pharmaceuticals
US6210908B1 (en) 1998-11-11 2001-04-03 Dade Behring Marburg Gmbh Activated peptides and conjugates
US6743585B2 (en) 1999-09-16 2004-06-01 Agilent Technologies, Inc. Methods for preparing conjugates
US6797521B2 (en) * 1999-10-26 2004-09-28 University Of Utah Research Foundation Fluorescent cobalamins and uses thereof
WO2012142659A1 (en) * 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
CN107973836B (zh) * 2017-10-19 2020-05-12 苏州博源医疗科技有限公司 醛固酮衍生物及其制备方法、醛固酮均相酶免疫检测试剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5272284A (en) * 1975-12-12 1977-06-16 Dainippon Pharmaceutical Co Enzymeeimmunoassay reagent
US4760142A (en) * 1984-11-27 1988-07-26 Hoechst Celanese Corporation Divalent hapten derivatives
JPH01199573A (ja) * 1987-10-25 1989-08-10 Kuraray Co Ltd スーパーオキシドジスムターゼ誘導体およびその製造法
US4994385A (en) * 1987-10-30 1991-02-19 Abbott Laboratories Heterobifunctional coupling agents
US5002883A (en) * 1987-10-30 1991-03-26 Abbott Laboratories Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents
CA1340387C (en) * 1987-10-30 1999-02-09 Carol A. Schlesinger Heterobifunctional coupling agents
EP0396116B1 (en) * 1989-05-02 1997-02-05 Abbott Laboratories Covalent attachment of specific binding members to a solid phase

Also Published As

Publication number Publication date
DE69323713T2 (de) 1999-07-01
AU3976393A (en) 1993-11-29
JPH06508639A (ja) 1994-09-29
EP0606411B1 (en) 1999-03-03
WO1993022677A1 (en) 1993-11-11
US5294536A (en) 1994-03-15
EP0606411A1 (en) 1994-07-20
CA2101734A1 (en) 1993-10-24
AU662627B2 (en) 1995-09-07
DE69323713D1 (de) 1999-04-08
ATE177113T1 (de) 1999-03-15

Similar Documents

Publication Publication Date Title
ES2130257T3 (es) Nuevos compuestos y conjugados.
ES2104333T3 (es) Alcoxilado de 2-propil-heptanol y su uso.
MX9300298A (es) Conjugados de tioeter y procedimiento para su preparacion
CL2009002199A1 (es) Anticuerpo que se une especificamente a epitope de cripto; composicion farmaceutica que comprende dicho anticuerpo; uso del anticuerpo para disminuir el crecimiento de un tumor in vitro; metodo para modular el crecimiento de celulas de tumor in vitro en una muestra; anticuerpo humanizado (div. sol. n° 831-2002).
DK1187601T3 (da) Hidtil ukendt præparat og administrationsform som omfatter en syrelabil protonpumpeinhibitor
AR020054A1 (es) COMPOSICIoN QUE COMPRENDE UN ADENOVIRUS
BR0111667A (pt) Novos compostos
BR0114646A (pt) anticorpos anti-lt-beta-r humanizados
DK1163008T3 (da) Anvendelse af trehalose til stabilisering af en flydende vaccine
CO5050303A1 (es) Composicion farmaceutica para tratar infecciones virales y metodos para su preparacion su aplicacion
MX9302214A (es) Derivados de taxol y proceso para su preparacion
CO5221123A1 (es) Desodorante con pequenas particulas de oxido de zinc
ES2104797T3 (es) Composiciones farmaceuticas con actividad antagonista de angiotensina-ii.
ES2127976T3 (es) Combustibles para motores otto que contienen polieteraminas.
SV1998000008A (es) Inhibisores de sulfamida-metaloproteasa. ref. ran 4070\114
ES2098921T3 (es) Composiciones de cetoconazol de uso topico.
ES2155070T3 (es) Conjugados peptido-carbohidrato que generan inmunidad por las celulas t.
AR024634A1 (es) Composicion farmaceutica estabilizada en forma liofilizada
AR016821A1 (es) Procedimiento mejorado para la obtencion de precursores de insulina con puentes de cistina correctamente unidos
AU3012701A (en) Use of methylchinolinium compounds for dyeing keratin containing fibers
AR003176A1 (es) Una composicion farmaceutica para inhibir el crecimiento de cancer
UA32522C2 (uk) Ліофілізована протипухлинна композиція і стерильна водна композиція для ін'єкцій на її основі
EA199901116A1 (ru) Композиция, включающая 5-[4-[2-(n-метил-n-2-пиридил)-амино)этокси]бензил]тиазолидин-2,4-дион
BR9814495A (pt) Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo
BR0011339A (pt) Composto, uso, e processo para preparar o mesmo, composição farmacêutica, e, método para tratar uma condição de doença mediada por metaloproteinase

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 606411

Country of ref document: ES